Arca
Skip to content

Warning Letter to BR SAS

Unspecified. See BR SAS's company page or this site's inspections.

On Jun 8, 2018, FDA's CDER sent BR SAS a warning letter citing sterility assurance, process validation, stability.

  • Letter date: Jun 8, 2018
  • Issued by: CDER
  • Closeout: —

The Letter

As posted on FDA.gov ↗; cited 21 CFR sections link to their page.

• all chemical and microbial test methods and specifications used to analyze each of your OTC drug products prior to a batch disposition decision;

• remediated microbiological testing methods (i.e., total counts and objectionable microbes) that conform to USP 61> and 62>. These methods should be capable of identifying all microorganisms in product bioburden to determine whether any are objectionable in view of the product’s intended use. --> -->

• a summary of test results obtained from testing retain samples of all OTC drug products within expiry that have been distributed in the United States. These test results should include identity and strength of active ingredients, and all other appropriate quality attributes.

• quality control release specifications for all incoming components, and the tests you perform for each lot;

• a summary of test results obtained from full testing of all your incoming components to validate the COA from each raw material manufacturer;

• a summary of your procedures for qualifying and overseeing the adequacy of contract facilities that test the OTC drug products you manufacture;

• a comprehensive, independent review of your material system to determine whether all containers, closures, and ingredients from each supplier are adequately qualified, assigned appropriate expiration or retest dates, and incoming material lot controls are adequate to prevent use of unsuitable containers, closures, and components.

• investigating deviations;

• conducting annual product quality reviews;

• investigating out-of-specification results;

• handling product returns;

• reprocessing and reworking;

• reconciling labels;

• creating batch records and issuing master batch records; and

• approving batch records and releasing batches.

Recent Letters Citing Sterility assurance

See them all

Record

Recipient
Mr. Pierre-Louis Delapalme
FDA site ID (FEI)
1000373305

Tags are assigned by Arca from the letter's text. A closeout letter means FDA found the firm's corrections adequate; no closeout does not mean the issues are unresolved. FDA warning letters

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.